Abu Dhabi Biobank wins AABB accreditation for cord blood banking

READY
Read by Emma, the Simply Abu Dhabi narrator.
A facility built to preserve possibility. Inside Abu Dhabi Biobank, cord blood from thousands of newborns sits in cryogenic storage, waiting. Each unit represents a choice a family made at the moment of birth: to save cells that might one day treat leukaemia, lymphoma, sickle cell disease, or therapies not yet imagined. The Association for the Advancement of Blood and Biotherapies, the gold standard for cord blood banking worldwide, has now accredited the facility, confirming that Abu Dhabi’s infrastructure for collecting, testing, processing and storing these cells meets the most rigorous international safety and quality standards.
The accreditation matters because it moves cord blood banking from novelty to trusted medicine. Globally, cord blood stem cells are already in clinical use for more than 80 medical conditions. The AABB standard means families who store units here have assurance that the cells will remain viable for decades, that donor screening and safety protocols match those in the world’s leading biobanks, and that the facility will operate to the same standard whether the technology changes or the people running it do. Abu Dhabi Biobank, a partnership between the Department of Health Abu Dhabi and M42, has been building toward this for years. Now it has the credential that positions it as the region’s hub for regenerative medicine and cellular therapy development.
The timing matters too. Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health Abu Dhabi, saw the accreditation as confirmation of a larger ambition. “This accreditation reinforces the pathway from research to clinical application,” she said, speaking directly to why a government invests in infrastructure like this: not for today’s patients alone, but to position the emirate for the therapies of tomorrow. Abu Dhabi is signalling to researchers, clinicians and pharmaceutical companies that it has built the foundation they need.
The facility operates the region’s largest hybrid cord blood bank and works across a network of hospitals including Danat Al Emarat, NMC Healthcare, Burjeel and Mediclinic. Paul Downey, General Manager, described the accreditation as reflecting the standard the facility holds itself to. “Our focus is on expanding access, strengthening collaboration with healthcare and research partners, and developing the capabilities that will support the future of cord blood banking, regenerative medicine and cellular therapies,” he explained. The public cord blood registry the biobank is building will mean donated units can be accessed for transplantation and research across the region, not just for families who can pay for private storage.
What sets Abu Dhabi’s approach apart is integration. The biobank connects cord blood banking, cryopreservation, fertility preservation and regenerative medicine research into a single ecosystem, working with Khalifa University and other research partners. The Annual Conference of Ob-Gyn for Research and Development Symposium, hosted at the facility itself, brought clinicians and researchers together to discuss innovations in stem cell applications and cellular therapy, followed by a tour of the biobank. That kind of infrastructure, where storage meets research and clinical care, is what attracts serious investment and partnership from companies like AstraZeneca, with whom the biobank has already partnered to advance predictive healthcare through artificial intelligence and genomic data.
For Abu Dhabi, the accreditation is a credential that opens doors. It signals to international life sciences companies and research institutions that the emirate is serious about building world-class capabilities in cellular medicine, not just investing in them. That matters for a region competing to attract the next generation of therapeutic development, and for families who want to know that the choice they make at a child’s birth is backed by internationally recognised standards.
The biobank operates the region’s largest hybrid cord blood bank and works with a network of partner hospitals including Danat Al Emarat Women’s and Children Hospital, NMC Healthcare, Burjeel and Mediclinic, alongside research partners such as Khalifa University. This integrated approach connects cord blood banking, cryopreservation, fertility preservation and regenerative medicine into a single national capability. The Annual CORD Symposium brought together key opinion leaders to discuss innovations in cord blood banking, stem cell applications, cellular therapy and the role of obstetricians and gynaecologists in routine maternity care, followed by a tour of the biobank facility.
What it means for Abu Dhabi
The AABB accreditation reinforces Abu Dhabi’s position as a regional leader in life sciences innovation and positions the emirate to attract international research partnerships and investment in advanced therapeutic development. By establishing internationally recognised standards for cord blood banking, Abu Dhabi strengthens its capability to support emerging cellular therapies and regenerative medicine applications that may benefit patients across generations.
The public cord blood registry planned by Abu Dhabi Biobank will expand access to donated units for transplantation and research throughout the region, creating opportunities for medical advancement while supporting the emirate’s broader health infrastructure. This ecosystem, connecting clinical care, research and therapeutic development, exemplifies Abu Dhabi’s commitment to building comprehensive capabilities in maternal and neonatal health alongside cutting-edge scientific innovation.
Source: WAM